Folgen
Julian Nam
Julian Nam
Hoffmann-La Roche Limited
Bestätigte E-Mail-Adresse bei mcmaster.ca
Titel
Zitiert von
Zitiert von
Jahr
Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS–NSTEMI …
J Layland, KG Oldroyd, N Curzen, A Sood, K Balachandran, R Das, ...
European heart journal 36 (2), 100-111, 2015
312*2015
Close contact casting vs surgery for initial treatment of unstable ankle fractures in older adults: a randomized clinical trial
K Willett, DJ Keene, D Mistry, J Nam, E Tutton, R Handley, L Morgan, ...
Jama 316 (14), 1455-1463, 2016
128*2016
The Ankle Injury Management (AIM) trial: a pragmatic, multicentre, equivalence randomised controlled trial and economic evaluation comparing close contact casting with open …
DJ Keene, D Mistry, J Nam, E Tutton, R Handley, L Morgan, E Roberts, ...
Health Technology Assessment (Winchester, England) 20 (75), 1, 2016
972016
Systematic review and meta-analysis of the benefits of out-of-hospital 12-lead ECG and advance notification in ST-segment elevation myocardial infarction patients
J Nam, K Caners, JM Bowen, M Welsford, D O'Reilly
Annals of emergency medicine 64 (2), 176-186. e9, 2014
842014
Intra-arterial thrombolysis vs. standard treatment or intravenous thrombolysis in adults with acute ischemic stroke: a systematic review and meta-analysis
J Nam, H Jing, D O'Reilly
International Journal of Stroke 10 (1), 13-22, 2015
482015
A parallel group randomised open blinded evaluation of Acceptance and Commitment Therapy for depression after psychosis: Pilot trial outcomes (ADAPT)
A Gumley, R White, A Briggs, I Ford, S Barry, C Stewart, S Beedie, ...
Schizophrenia Research 183, 143-150, 2017
452017
Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC)
U Ondhia, HJ Conter, S Owen, A Zhou, J Nam, S Singh, A Abdulla, P Chu, ...
Journal of medical economics 22 (7), 625-637, 2019
262019
Bayesian solutions for handling uncertainty in survival extrapolation
MA Negrín, J Nam, AH Briggs
Medical Decision Making 37 (4), 367-376, 2017
242017
Comprehensive genomic profiling for non-small-cell lung cancer: health and budget impact
KM Johnston, BS Sheffield, S Yip, P Lakzadeh, C Qian, J Nam
Current Oncology 27 (6), 569-577, 2020
202020
Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST segment elevation myocardial infarction (FAMOUS-NSTEMI) developmental …
J Nam, A Briggs, J Layland, KG Oldroyd, N Curzen, A Sood, ...
Cost Effectiveness and Resource Allocation 13, 1-9, 2015
172015
Evaluation of health in pregnancy grants in Scotland: a natural experiment using routine data
AH Leyland, S Ouédraogo, J Nam, L Bond, AH Briggs, R Gray, R Wood, ...
Public Health Research 5 (6), 2017
162017
Costs of in-house genomic profiling and implications for economic evaluation: A case example of non-small cell lung cancer (NSCLC)
KM Johnston, BS Sheffield, S Yip, P Lakzadeh, C Qian, J Nam
Journal of Medical Economics 23 (10), 1123-1129, 2020
152020
Economic evaluation of rituximab in addition to standard of care chemotherapy for adult patients with acute lymphoblastic leukemia
J Nam, R Milenkovski, S Yunger, M Geirnaert, K Paulson, M Seftel
Journal of Medical Economics 21 (1), 47-59, 2018
102018
Health and budget impact of liquid-biopsy-based comprehensive genomic profile (CGP) testing in tissue-limited advanced non-small cell lung cancer (aNSCLC) patients
YP Patel, D Husereau, NB Leighl, B Melosky, J Nam
Current Oncology 28 (6), 5278-5294, 2021
82021
PPM11 tumour-specific randomized controlled trials in rare oncogene-driven cancers: asking for the impossible?
G Lozano-Ortega, M Hodgson, F Csintalan, C Zerbini, K Johnston, J Nam
Value in Health 22, S838-S839, 2019
82019
Reverse engineering of digital measures: inviting patients to the conversation
I Clay, N Peerenboom, DE Connors, S Bourke, A Keogh, K Wac, ...
Digital Biomarkers 7 (1), 28-44, 2023
62023
Fractional flow reserve versus Coronary Angiography guided management in non-st elevation myocardial infarction: a Health economic analysis
J Nam, A Briggs, J Layland, K Oldroyd, N Curzen, A Sood, ...
Value in Health 18 (3), A46, 2015
22015
PPM5 costs of in-house mutational-testing and implications for economic evaluation: a case example of non-small cell lung cancer (NSCLC)
J Nam, P Lakzadeh, K Johnston, S Yip, C Qian, B Sheffield
Value in Health 22, S837-S838, 2019
12019
PPM4 Comprehensive genomic profiling for non-small cell lung cancer (NSCLC): a health and budget impact analysis
J Nam, K Johnston, S Yip, C Qian, P Lakzadeh, B Sheffield
Value in Health 22, S837, 2019
12019
OP86 Evaluating Health in Pregnancy grants in Scotland: a natural experiment
AH Leyland, S Ouédraogo, R Gray, L Bond, AH Briggs, J Nam, R Wood, ...
J Epidemiol Community Health 70 (Suppl 1), A47-A48, 2016
12016
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20